#USA #Washington #Nereus #Vanda Pharmaceuticals #Fanapt

Vanda Pharmaceuticals Achieves Impressive Growth in Q1 2026, Introducing Innovative Drugs

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

On May 6, 2026, Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shared its financial performance and operational progress for the first quarter ended March 31, 2026. The company noted remarkable milestones and growth trajectories with several products, driving optimism for future performance.

Vanda’s flagship product, Fanapt®, saw a net sales increase of 26%, reaching $29.6 million. This uptick in sales was attributed to a 32% rise in total prescriptions alongside an astounding 76% surge in new-to-brand prescriptions. Notably, in April 2026, weekly prescriptions for Fanapt hit an 11-year high, marking a promising upward trend as the company implements robust marketing strategies.

The launch of NEREUS™ (tradipitant) represents a pivotal moment for Vanda. This is the first new prescription medication approved in more than 40 years for preventing motion-related vomiting. Vanda's innovative direct-to-consumer platform, nereus.us, has enhanced accessibility, allowing patients to order online with rapid home delivery. This breakthrough addresses a longstanding gap in treatment options within the consumer health-market, reflecting Vanda’s commitment to patient-centric care.

Vanda’s revenue for Q1 2026 totaled $51.7 million, a 3% increase year-over-year compared to $50.0 million in Q1 2025. However, the company reported a net loss of $48.6 million, attributed to investments in product launches and pipeline developments, reflecting the company’s ongoing strategy to innovate and expand its offerings. As of the end of Q1 2026, Vanda maintained cash reserves of $202.3 million, factoring in a one-time payment related to the NEREUS launch.

Looking forward, Vanda has revised its full-year revenue guidance for 2026, projecting total revenues between $240 million and $290 million, taking into account anticipated contributions from the newly launched NEREUS. Specific estimates for NEREUS sales are estimated at $10 million to $30 million, showcasing the company’s confidence in the product amidst a dynamic marketplace.

In addition to positive sales trends, Vanda achieved regulatory success with the FDA's approval of BYSANTI™ (milsaperidone) for treating bipolar I disorder and schizophrenia. This adds another innovative treatment option to Vanda's portfolio, while BYSANTI is protected under multiple patents until 2044, securing market exclusivity and potential revenue streams for years ahead.

Vanda’s efforts continue in advancing clinical developments, highlighted by the acceptance of the Biologics License Application (BLA) for imsidolimab, intended for treatment of Generalized Pustular Psoriasis (GPP), whose target action date is set for December 12, 2026. Promising late-stage studies for BYSANTI as a treatment for major depressive disorder and ongoing assessments for NEREUS's additional applications demonstrate Vanda’s dedicated pursuit to address complex health issues.

In corporate news, Vanda appointed Charles Duncan, Ph.D. to its Board of Directors, expanding its leadership team to include diverse insights and governance.

Conclusion

Vanda’s financial and operational results for Q1 2026 underscore a significant momentum driven by innovative product launches like NEREUS and a steady increase in prescriptions for Fanapt. With a solid strategy and a focus on unmet medical needs, Vanda Pharmaceuticals is poised for continued growth and enhanced patient outcomes in the biopharmaceutical landscape. Interested parties can join the live conference call scheduled for today, May 6, 2026, to discuss the details of these accomplishments and future objectives.

For more information, visit Vanda Pharmaceuticals.